Fully vaccinated people carry 251 times the viral load of COVID-19, according to a new study.
Source: Andrew White
A new study has revealed that people who are “fully vaccinated” carry a staggering 251 times the normal viral load of COVID-19. Experts are concerned that this may pose a risk to those who have not received the COVID-19 vaccine, and it also seems likely these increased viral loads could result in more so-called “breakthrough” cases of those who have been vaccinated contracting COVID-19.
A study by the Oxford University Clinical Research Group published on August 10th in The Lancet found that fully vaccinated people carry 251 times the viral load of coronavirus as compared to those who have not received one of the controversial vaccines. “Viral loads of breakthrough Delta variant infection cases were 251 times higher than those of cases infected with old strains detected between March-April 2020,” reads the study.
The vaccines seem to allow vaccinated individuals to carry unusually high viral loads without becoming sick, transforming them into super spreaders who experience symptoms later on, as reported by Daily Veracity:
The study focused on healthcare workers who were unable to leave the hospital for two weeks. The study showed that fully vaccinated workers, about two months after injection, carried and transmitted the virus to their vaccinated colleagues after infection.
They also passed the virus to unvaccinated people, including their patients. The vaccine used in the study was the Oxford/AstraZeneca (AZD1222) vaccine.
In reaction to the study, Congressman Paul Gosar (R-AZ), tweeted “as we have said—side effects and efficacy are measured in years. Not weeks and months. Another study that should cause all reasonable people to pause.”
The Food and Drug Administration (FDA) on Monday granted full approval for the Pfizer-BioNTech COVID-19 vaccine, opening the door for vaccine mandates across the US. This comes just days after the Director of the Center for Disease Control (CDC) Rochelle Walensky admitted that COVID-19 “vaccine effectiveness against SARS-CoV-2 is waning,” adding that those who were “vaccinated early” are at an “increased risk of severe disease.”
SEC filings have shown that Moderna has made $12 billion as the government and major institutions push for forced vaccinations, as was previously reported by National File. Stéphane Bancel, the Chief Executive Officer of Moderna said they are “looking forward towards our vision of a single dose annual booster that provides protection against COVID-19, flu and RSV for adults. I look forward to the start of our Phase 3 trial for CMV this year and to clinical proof of concept data in the coming quarters from our therapeutics pipeline. We believe this is just the beginning.”